Literature DB >> 1724644

Treatment of lower extremity infections in diabetics.

W S Joseph1.   

Abstract

Despite recent medical advances in the treatment of diabetes mellitus, foot infection remains a major cause of morbidity and mortality in patients with this disorder. Three main factors are responsible for this: neuropathy, angiopathy and immunopathy. Neuropathy is probably the most important factor: minor irritations and trauma can lead to limb-threatening infections without the patient feeling the changes. Angiopathy plays only a minor role, while immunopathy has implications for antibiotic treatment, in that bactericidal agents are needed. A classification scheme that incorporates clinical and laboratory findings can direct the selection of empirical antibiotic therapy in patients with foot infections. These infections may be defined as mild, moderate and severe. In less severe cases, there are effective oral agents that can stop the progress of the infection and obviate the need for patient hospitalisation. Moderate to severe infections require hospitalisation with the use of parenteral agents. With some of the new broad spectrum drugs, single agent therapy is now possible, eliminating the need for expensive, potentially toxic combinations. Antibiotics, however, are only part of the cure. Aggressive surgical debridement followed by conscientious local wound care plays an equal role. The ultimate goal is foot salvage, and the clinical judgement of the practitioner is paramount in determining the treatment strategies needed to achieve this objective.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1724644     DOI: 10.2165/00003495-199142060-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  25 in total

Review 1.  Aldose reductase inhibitors in the treatment of diabetic neuropathy. A review of the rationale and clinical evidence.

Authors:  E A Masson; A J Boulton
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

2.  Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate.

Authors:  K I Plaisance; G L Drusano; A Forrest; R J Townsend; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

3.  The dysvascular foot: a system for diagnosis and treatment.

Authors:  F W Wagner
Journal:  Foot Ankle       Date:  1981-09

Review 4.  Acute and chronic complications of diabetes mellitus in older patients.

Authors:  D A Greene
Journal:  Am J Med       Date:  1986-05-16       Impact factor: 4.965

5.  Outpatient management of uncomplicated lower-extremity infections in diabetic patients.

Authors:  B A Lipsky; R E Pecoraro; S A Larson; M E Hanley; J H Ahroni
Journal:  Arch Intern Med       Date:  1990-04

6.  The fetid foot: lower-extremity infections in patients with diabetes mellitus.

Authors:  J Fierer; D Daniel; C Davis
Journal:  Rev Infect Dis       Date:  1979 Jan-Feb

7.  Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital.

Authors:  I Shalit; S A Berger; A Gorea; H Frimerman
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

Review 8.  Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Ward; D M Richards
Journal:  Drugs       Date:  1985-11       Impact factor: 9.546

9.  Quantitative aerobic and anaerobic bacteriology of infected diabetic feet.

Authors:  F L Sapico; H N Canawati; J L Witte; J Z Montgomerie; F W Wagner; A N Bessman
Journal:  J Clin Microbiol       Date:  1980-09       Impact factor: 5.948

Review 10.  Hypertension in the diabetic patient. Selection and optimum use of antihypertensive drugs.

Authors:  B N Trost
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

View more
  1 in total

1.  Infections in Diabetic Foot Ulcerations.

Authors:  Warren S. Joseph; James S. Tan
Journal:  Curr Infect Dis Rep       Date:  2003-10       Impact factor: 3.725

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.